These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 11234294

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.
    Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT.
    Pharmacogenetics; 1999 Feb; 9(1):71-80. PubMed ID: 10208645
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes.
    Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivistö KT.
    Clin Pharmacol Ther; 2002 Sep; 72(3):326-32. PubMed ID: 12235454
    [Abstract] [Full Text] [Related]

  • 26. Genetic regulation of warfarin metabolism and response.
    Daly AK, Aithal GP.
    Semin Vasc Med; 2003 Aug; 3(3):231-8. PubMed ID: 15199455
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose.
    Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, Mrhar A, Breskvar K, Dolzan V.
    Pharmacogenomics J; 2005 Aug; 5(3):193-202. PubMed ID: 15824753
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects.
    Spaans E, van den Heuvel MW, Schnabel PG, Peeters PA, Chin-Kon-Sung UG, Colbers EP, Sitsen JM.
    Eur J Clin Pharmacol; 2002 Sep; 58(6):423-9. PubMed ID: 12242602
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E, Cloyd J, Critchley D, Fuseau E.
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [Abstract] [Full Text] [Related]

  • 37. CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.
    Twardowschy CA, Werneck LC, Scola RH, De Paola L, Silvado CE.
    Arq Neuropsiquiatr; 2011 Apr; 69(2A):153-8. PubMed ID: 21537551
    [Abstract] [Full Text] [Related]

  • 38. CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.
    Franco V, Perucca E.
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(8):1269-79. PubMed ID: 26037375
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.